Health outcomes versus income: the balance of value and cost in cancer care

As access to and affordability of innovative cancer treatments climbs the political ladder and increasingly becomes one of the most difficult health economic issues on the global agenda, analyst Global Insight has reviewed recent cost-effectiveness appraisals and what they mean for developing pricing strategies. Its key findings are:

- while clinical health outcomes are showing major advances in the field of oncology, the global picture of market access has made for a bleak assessment for pharmaceutical companies;